Journal of Clinical Oncology
Articles in this Issue
Effect of HOXB7 on oxaliplatin resistance in colon cancer through glutamine metabolic reprogramming via non-canonical activation of YAP1.
e15732 Background: Colorectal adenocarcinoma (COAD) ranks as the third most commonly diagnosed cancer and the third leadin...
Co-operation of contralateral prophylactic mastectomy and risk-reducing salpingo-oophorectomy in Korean breast cancer patients with germline <i>BRCA1/2</i> mutation.
e22651 Background: Carriers of germline BRCA1/2 pathogenic variants are considered...
National trends in opioid-related hospitalizations among adult cancer patients: 2000-2022.
11147 Background: Opioid use disorder is increasingly prevalent among cancer patients. Since mid-2010s, heightened attenti...
Efficacy and safety of mevrometostat (M) in combination with enzalutamide (E) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Data from a phase 1 study.
e17043 Background: M is a potent and selective inhibitor of enhancer of zeste homolog 2. M 1250 mg twice daily (BID) on an...
Patterns of tumor regression after neoadjuvant immunochemotherapy in oral squamous cell carcinoma and their surgical margin implications.
6098 Background: Neoadjuvant immunochemotherapy (nICT) has been increasingly applied in locally advanced oral squamous cel...
Can TGF-β inhibition (galunisertib) enhance response to enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)?: Results from a randomized phase II trial.
5056 Background: Resistance to androgen receptor (AR)-directed therapies is a major challenge in advanced prostate cancer,...
Chemoimmunotherapy with or without locoregional therapy for biliary tract cancer: A propensity score–matched study.
e16185 Background: , Recent phase II studies, including MISPHERE and ABC-07, suggest benefit from combining locoregional t...
Efficacy of durvalumab and safety by treatment period in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy in resectable gastric/gastroesophageal junction (G/GEJ) cancer.
4070 Background: In MATTERHORN (NCT04592913), perioperative durvalumab (D) + FLOT significantly improved event-free surviv...
A subset analysis of clinical activity and pharmacodynamic biomarkers in patients with sarcomas in the phase 1 dose-escalation study of STC-15, a METTL3 inhibitor.
11548 Background: The RNA methyltransferase METTL3 is responsible for the generation of N6-methyladenosine (m6A), the most...
Trends in disability-adjusted life years from hepatitis C–related liver cancer in the United States: A Global Burden of Disease study.
e16194 Background: Hepatitis C virus (HCV)–related mortality has declined in the United States, largely due to the widespr...
Phase II study of adjuvant nab-paclitaxel plus S-1 after D2 resection in stage III diffuse gastric cancer (NORDICA study).
4085 Background: Stage III diffuse-type gastric cancer (DGC) is highly aggressive, with a substantial risk of postoperativ...
SILVER (supplementing tebentafusp with subcutaneous IL-2 to verifiably eradicate radiological progression): A phase 1/2 trial of IL-2 with tebentafusp upon first radiological progression on first-line tebentafusp alone.
TPS9606 Background: Metastatic uveal melanoma (mUM) remains a disease with a profound unmet clinical need. Tebentafusp, a...
A US-based, retrospective, observational study of biomarker testing patterns across lines of therapy in patients with metastatic colorectal cancer.
e15526 Background: As the third most prevalent and third leading cause of cancer-related deaths in the US, colorectal canc...
Patient-reported outcomes from IMvigor011: A phase 3 study of circulating tumor (ct)DNA–guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer (MIBC).
4627 Background: IMvigor011 (NCT04660344) showed that serial ctDNA-based molecular residual disease (MRD) monitoring can i...
From Bayesian dose-finding to AI-enabled decision support in oncology clinical trials.
e15145 Background: Bayesian methods are increasingly used in oncology clinical development to support dose finding, adapti...
Urinary RNA as response predictor for patients with metastatic urothelial carcinoma treated with pembrolizumab.
e16591 Background: Limited biomarkers are available to predict response and outcome in metastatic urothelial carcinoma (mU...
Impact of academic center–based care on clinical outcomes in light chain amyloidosis.
e13798 Background: Light chain (AL) amyloidosis requires coordinated hematologic and organ-specific care, often delivered...
Longitudinal overview of mortality for malignant neoplasm of the brain and cerebrovascular diseases in the U.S. from 1999 to 2023 using CDC WONDER.
e14024 Background: Malignant brain tumors and cerebrovascular diseases are major contributors to mortality in the United S...
Paclitaxel plus bevacizumab with or without atezolizumab for hormone receptor-positive/HER2-negative advanced breast cancer: JCOG1919E (AMBITION) phase III trial.
1019 Background: Hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC) is immunologically “cold...
Neoadjuvant combination versus single-agent immune checkpoint inhibition in locally advanced MSI-H/dMMR colorectal cancer: A systematic review and meta-analysis.
e15595 Background: Immune checkpoint inhibitors (ICIs) have transformed treatment for MSI-H/dMMR colorectal cancer (CRC)....
Accelerate tobacco treatment in cancer care with evidence-based implementation strategies: How to get from here to there?
e13548 Background: Tobacco use is associated with 40% of all cancer diagnoses in the United States. Individuals with cance...
Pan-cancer landscape of oncogenic POLE and POLD1 alterations.
2650 Background: POLE and POLD1 encode key enzymes for DNA proofreading. Oncogenic alterations in POLE and POLD1 associate...
Patient-reported digital symptom monitoring and actionable triage in oncology: A scoping systematic review.
e23274 Background: Treatment-related symptoms substantially impair quality of life (QoL) and drive unplanned acute care us...
A randomized trial of sentinel node biopsy omission after neoadjuvant systemic therapy in clinically node-negative or selected node-positive breast cancer.
TPS651 Background: Omission of axillary surgery has been established as a safe option in selected patients with early-stag...
Does PSA at diagnosis correlate with Decipher Score?
e17139 Background: The Decipher genomic classifier is a validated molecular biomarker that examines the activity of 22 gen...